Therapeutic Effect of Chitosan Nanoparticles and Amikacin in Treatment of Experimentally Escherichia bacteria isolated from diarrheal cases


  • Waleed Abdulkhaleq Ahmed Al-Janabi College of Medicine, University of Wasit, Iraq
  • Alaa Mohaisen Al-Rubae College of Medicine, University of Wasit, Iraq.
  • Basim A. Fayyadh paediatric Basra Childrens Specialist Hospita, Iraqi Ministry of Health, Basra, Iraq
  • Ali abdl Husseen jawad Al-Zahra Teaching Hospital, Wasit Health Directorate, Iraqi Ministry of Health, Wasit, Iraq
  • Raed shakir shnain Aheed fayrooz hospital, Wasit Health Directorate, Iraqi Ministry of Health, Wasit, Iraq



Chitosan nanoparticles, amikacin


Background: The application of nanotechnology in medicine, especially in drug delivery, will rapidly spread. Many substances are currently being investigated for drug delivery in order to the treatment of various diseases. The present study aimed to assess the effect of Chitosan Nanoparticles and Amikacin in Treatment of experimentally Escherichia coli bacteria isolated from diarrheal cases as well as evaluate the efficacy of loading Amikacin on chitosan nanoparticles.

Methods: This study was carried out at medicine Department, college of Medicine, Wasit University and lab tore of Al-Batool Hospital in Wasit Governorate from February 2022 to February 2023. The study was conducted on 60 children (males and females) under the age of 5 years who were diagnosed with Escherichia coli bacterial infection from cases of diarrhea for patients in Al-Batool Hospital in the city of Wasit.

All samples were grouped into three groups: group A include E. coli infected individual treated with Amikacin alone, group B include E. coli infected individual treated with Chitosan nanoparticles alone and group C include E. coli infected individual treated with Chitosan nanoparticles and Amikacin.

Results: The highest percentages of reduction inhibition were in group that received mixed Chitosan nanoparticles and Amikacin treatment (67.34). Lower percentages of reduction were recorded for TRI only treated group (58.15%). where the incidence of E. coli in males was higher than that of females (61.51%) and (60.33%) respectively.


Download data is not yet available.


Ahmed, A. A. (2009): Study of Antibiotic resistance of Escherichia coli isolated from children's diarrhea. Al Anbar University Journal, 1(3): 1-6.

Alain, L.S.(2005). Mechanism by which the disease is thought to be induced: ETEC, EPEC, EHEC, EAEC, DACE, EAEC. Clinical Microbiology Rev., 18:264-292.

Borm PJ, Muller-Schulte D. (2006): Nanoparticles in drug delivery and environmental exposure: same size, same risks? Nanomedicine; 1:235–49.

Brown, S.; Santa Maria, J.P., Jr.; Walker, S. Wall teichoic acids of gram-positive bacteria. Annu. Rev. Microbiol. 2013, 67, 313–336.

Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Tenth Edition. CLSI document M07- A10, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.

Doyle, M.P.; Beuchat, L.R.; Montville, T.J. (1997). "Food Microbiology, Fundamentals and Frontiers, ASM Press. Washington. D.C. pp: 129- 131.

Elzatahry AA, Eldin MSM. (2008): Preparation and characterization of metronidazole-loaded chitosan nanoparticles for drug delivery application. Polym Adv Technol.; 19(12):1787– 91.

Hu YL, Qi W, Han F, et al. Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model. Int J Nanomedicine. 2011; 6:3351-9

Jong, w. and Borm P. (2008): Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine ; 3(2): 133–149.

Khalid, S.; Piggot, T.J.; Samsudin, F. Atomistic and Coarse Grain Simulations of the Cell Envelope of Gram-Negative Bacteria: What Have We Learned? Acc. Chem. Res. 2019, 52, 180–188.

Kim S. Competitive biological activities of chitosan and its derivatives: antimicrobial, antioxidant, anticancer, and anti-inflammatory activities. Int J Polym Sci. 2018; 2018:1-13.

Koneman, E.W.; Allen, S.D.; janda, W. M.; Dowell, V. R.; Sommer, H. M. and Wonn, W.C.(1997). “Color Atlas and Textbook of Diagnostic Microbiology”. 4th .ed. J.B.Lippincott Comp., Philadelphia.

Tang, C.H.; Hsu, C.J.; Yang, W.H.; Fong, Y.C. Lipoteichoic acid enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, PKCdelta and c-Src dependent pathways. Biochem. Pharmacol. 2010, 79, 1648–1657.

Viboud, G.I.; Jouve, M.J.; Binsztein, N.; Vergara, M.; Quiroga, M.(1999). Prospective cohort study of enterotoxigenic E. coli infections Argentinean children. J. clin. Microbial., 37: 2829-2833.

Wardani G, Eraiko K, Koerniasari K, et al. Protective activity of chitosan nanoparticle against cadmium chloride induced gastric toxicity in rat. J Young Pharm. 2018; 10(3):303–7.

Yan D.; Li Y.; Liu Y.; Zhang X. and Yan C. (2021): Antimicrobial Properties of Chitosan and Chitosan Derivatives in the Treatment of Enteric Infections. s. Molecules, 26, 7136.




How to Cite

Waleed Abdulkhaleq Ahmed Al-Janabi, Alaa Mohaisen Al-Rubae, Basim A. Fayyadh, Ali abdl Husseen jawad, & Raed shakir shnain. (2023). Therapeutic Effect of Chitosan Nanoparticles and Amikacin in Treatment of Experimentally Escherichia bacteria isolated from diarrheal cases. INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES, 2(11), 113–117.